KADRİYE BİR YUCEL, OSMAN SUTCUOGLU, TUBA UGUR, CİSEM CAGDASER, OZAN YAZİCİ, AHMET OZET, NURİYE OZDEMİR
Eurasian Journal of Medical Investigation - 2023;7(4):433-439
Objectives: The aim of this research was to assess the prognostic value of Gustave-Roussy immune score (GRIm-Score) in stage II and III colon cancer patients receiving capecitabine and oxaliplatin (CAPEOX). Methods: Serum lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR), and albumin levels were used to create the GRIm-Score. The GRIm-score was obtained with the sum of these three laboratory parameters, which were scored as 0 and 1 according to the cut-off values. A homogeneous patient group (high-risk stage II and stage III patients) was classified into two groups, one with a high GRIm-Score (score 2 and 3) and the other with a low GRImScore (score 0 and 1). Results: The 4-year recurrence-free survival (RFS) was 60% in the GRIm-Score high group and 94.4% in the GRIm-Score low group (p<0.001). The 4-year overall survival (OS) was 78.1% in the GRIm-Score high group and 93.8% in the GRImScore low group (p<0.001). Additionally, multivariable analyses revealed that GRIm-Score (HR: 4.226, 95% CI: 1.953- 9.143, p <0.001) was an independent prognostic marker for OS. Conclusion: High GRIm-Score was significantly related to poor OS in stage II and III colon cancer patients who received CAPEOX.
